Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
Lavin declaration - This is evidence that none of the patients in the katayama study had TG>=500
Applicant's arguments (read page 7 on interview summary with the examiner's supervisor) http://www.scribd.com/doc/93949302/Marine-patent-applicant-arguments
Dr. Reddy's v Astrazeneca (case law towards "claimed lipid parameters should be accorded patentable weight")
Composition of matter
Their 598 COM patent IMO is somewhat weak. It is good to prevent generics but maybe not so good to prevent slightly changed copycats(of course the copycats may have to run clinical trials). I like the main claim(s) in this new patent app. "A pharmaceutical composition comprising EPA and a cardiovascular agent, wherein the composition contains not more than 10% DHA by weight, if any."